Castle Biosciences (CSTL) vs Lumexa Imaging (LMRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lumexa Imaging is the larger company by market cap ($1.37 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSTL | LMRI |
|---|---|---|
| Share price | $32.86 | $14.26 |
| Market cap | $1.01B | $1.37B |
| 1-day change | -1.63% | +1.42% |
| YTD return | -15.53% | -22.92% |
| 1-year return | -13.25% | — |
| 5-year return | -23.79% | — |
| Forward P/E | — | 15.18 |
| EPS (TTM) | $-0.76 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $344.23M | — |
| Revenue growth (YoY) | +3.66% | — |
| Net income (latest FY) | $-24.16M | — |
| Gross margin | 79.37% | — |
| Operating margin | -12.44% | — |
| Net margin | -7.02% | — |
| 52-week high | $44.28 | $19.45 |
| 52-week low | $17.72 | $6.45 |
| Distance from 52-week high | -25.79% | -26.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.68% | +31.70% |
| Average volume | 382.23K | 372.45K |
| Shares outstanding | 30.82M | 96.12M |
| Employees | 1,048 | 5,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,048 employees
About Lumexa Imaging
LMRI stock →Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.
Health Care · Medical Specialities · 5,000 employees
CSTL vs LMRI FAQ
Which is bigger, Castle Biosciences or Lumexa Imaging?
Lumexa Imaging (LMRI) is larger, with a market capitalization of $1.37B compared with $1.01B for Castle Biosciences (CSTL).
Are Castle Biosciences and Lumexa Imaging in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.